Under AD-FMT treatment, we observed evident C/EBPβ/AEP signaling activation, accompanied by discernable APP N585 and Tau N368 fragmentation (Fig. 2A, B), which were in alignment with elevated mouse Aβ42 and aggregated Aβ and Tau (Fig. 1). The gene discussed is MAPT; the disease is Alzheimer disease.